1,855 results match your criteria Veno-occlusive Hepatic Disease


Ultrasound elastography techniques for diagnosis and follow-up of hepatic veno-occlusive disease.

Bone Marrow Transplant 2019 Jan 24. Epub 2019 Jan 24.

Hematology and Bone Marrow Transplantation Unit, IRCCS San Raffaele Scientific Institute, Milano, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-019-0432-5DOI Listing
January 2019
1 Read

The incidence and risk factors of hepatic veno-occlusive disease after hematopoietic stem cell transplantation in Taiwan.

Ann Hematol 2019 Mar 21;98(3):745-752. Epub 2019 Jan 21.

Department of Pediatrics, National Taiwan University Hospital, National Taiwan University, College of Medicine, No. 8 Chung-Shan South Road, Taipei, 10041, Taiwan.

Hepatic veno-occlusive disease (VOD) is a potentially fatal complication of hematopoietic stem cell transplantation (HSCT). We conducted this study to investigate the incidence and risk factors of hepatic VOD for patients receiving HSCT in Taiwan. We retrospectively analyzed the data from a nationwide registry for patients receiving HSCT, which was collected by the Taiwan Society of Blood and Marrow Transplantation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-019-03604-2DOI Listing
March 2019
2 Reads

Liver Stiffness Measurement Allows Early Diagnosis of Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome in Adult Patients Who Undergo Hematopoietic Stem Cell Transplantation: Results from a Monocentric Prospective Study.

Biol Blood Marrow Transplant 2019 Jan 18. Epub 2019 Jan 18.

Institute of Hematology L. and A Seràgnoli, Sant'Orsola Malpighi University Hospital, Bologna, Italy.

Veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), is a life-threatening complication affecting patients undergoing hematopoietic stem cell transplantation (HSCT). The survival rate is higher when specific therapy is initiated early; thus, improving early, noninvasive diagnosis of VOD/SOS is an important need. In an adult population undergoing HSCT, we aimed to assess the role of liver stiffness measurement (LSM), evaluated by transient elastography (TE), for diagnosing VOD/SOS. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.01.019DOI Listing
January 2019
3 Reads

No free rides: management of toxicities of novel immunotherapies in ALL, including financial.

Hematology Am Soc Hematol Educ Program 2018 11;2018(1):25-34

Division of Hematology and Bone Marrow Transplant, Mayo Clinic, Rochester, MN.

Therapeutic options for acute lymphoblastic leukemia, especially in the relapsed/refractory setting, have expanded significantly in recent times. However, this comes at the cost of toxicities: medical as well as financial. We highlight some of the unique toxicities associated with the novel agents to apprise our readers about what to expect, how to recognize them, and how to manage these toxicities. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/asheducation-2018.1.25DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6246022PMC
November 2018
4 Reads

Pyrrolizidine alkaloid-induced alterations of prostanoid synthesis in human endothelial cells.

Chem Biol Interact 2019 Jan 19;298:104-111. Epub 2018 Nov 19.

German Federal Institute for Risk Assessment, Department Food Safety, Berlin, Germany. Electronic address:

Pyrrolizidine alkaloids (PA) are a group of secondary plant metabolites belonging to the most widely distributed natural toxins. PA intoxication of humans leads to severe liver damage, such as hepatomegaly, hepatic necrosis, fibrosis and cirrhosis. An acute consequence observed after ingestion of high amounts of PA is veno-occlusive disease (VOD) where the hepatic sinusoidal endothelial cells are affected. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cbi.2018.11.007DOI Listing
January 2019
14 Reads

Risk factors for hepatic veno-occlusive disease caused by Gynura segetum: a retrospective study.

BMC Gastroenterol 2018 Oct 26;18(1):156. Epub 2018 Oct 26.

Department of Gastroenterology, The First Affiliated Hospital of Zhengzhou University, 1 Jianshe Donglu, Zhengzhou, 450052, Henan, China.

Background: Hepatic veno-occlusive disease (HVOD) caused by Gynura segetum has been increasingly reported in China in recent years. The aim of this retrospective study was to identify independent prognostic markers for survival in patients with Gynura segetum-induced HVOD and to evaluate the effect of anticoagulants and transjugular intrahepatic portosystemic shunt (TIPS) on survival rate.

Methods: Clinical data including symptoms, signs, imaging characteristics, laboratory test results, results of liver tissue biopsies, type of treatment during follow-up and clinical outcomes were collected. Read More

View Article

Download full-text PDF

Source
https://bmcgastroenterol.biomedcentral.com/articles/10.1186/
Publisher Site
http://dx.doi.org/10.1186/s12876-018-0879-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6204041PMC
October 2018
15 Reads
2.370 Impact Factor

Treatment of hepatic veno-occlusive disease in children with N-acetylcysteine.

Pediatr Blood Cancer 2019 Feb 23;66(2):e27518. Epub 2018 Oct 23.

Parkway Cancer Centre, Gleneagles Hospital, Singapore, Singapore.

In our institution, hepatic veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) has been treated with N-acetylcysteine (NAC) since 2008-a loading dose of 150 mg/kg, followed by 12 doses of 70 mg/kg 6 hourly. Nine children were diagnosed with hepatic VOD/SOS. Hepatic VOD/SOS occurred in seven children after stem cell transplantation and two were receiving chemotherapy for Wilms tumor. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/pbc.27518
Publisher Site
http://dx.doi.org/10.1002/pbc.27518DOI Listing
February 2019
4 Reads

Soluble Thrombomodulin Attenuates Endothelial Cell Damage in Hepatic Sinusoidal Obstruction Syndrome.

In Vivo 2018 Nov-Dec;32(6):1409-1417

Department of Gastroenterological Surgery, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan.

Background: Hepatic sinusoidal obstruction syndrome (SOS), also known as veno-occlusive disease, is a form of drug-induced liver injury, the initial morphological changes associated with which occur in liver sinusoidal endothelial cells (LSECs). Recombinant human soluble thrombomodulin (rTM) is reported to have anti-inflammatory and cytoprotective effects. Therefore, we investigated the ability of rTM to protect endothelial cells and enhance their functions in a monocrotaline (MCT)-induced model of SOS. Read More

View Article

Download full-text PDF

Source
http://iv.iiarjournals.org/lookup/doi/10.21873/invivo.11393
Publisher Site
http://dx.doi.org/10.21873/invivo.11393DOI Listing
January 2019
10 Reads

Defibrotide for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome with multiorgan failure.

Int J Hematol Oncol 2017 Nov 11;6(3):75-93. Epub 2017 Aug 11.

Department of Pediatric Hematology, Oncology & Stem Cell Transplantation, University of Regensburg, Regensburg, Germany.

Hepatic veno-occlusive disease, also called sinusoidal obstruction syndrome (VOD/SOS), is a potentially life-threatening and unpredictable complication of hematopoietic stem cell transplantation (HSCT). Characterized by a prothrombotic-hypofibrinolytic state, VOD/SOS typically presents with hyperbilirubinemia, ascites, weight gain and painful hepatomegaly; VOD/SOS with multiorgan failure may be associated with >80% mortality. Treatment has been mainly supportive. Read More

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/ijh-2017-0015
Publisher Site
http://dx.doi.org/10.2217/ijh-2017-0015DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6171967PMC
November 2017
14 Reads

Transient Elastography (TE) is a Useful Tool for Assessing the Response of Liver Iron Chelation in Sickle Cell Disease Patients.

Mediterr J Hematol Infect Dis 2018 1;10(1):e2018049. Epub 2018 Sep 1.

Second Academic Department of Medicine, School of Medicine, National and Kapodistrian University of Athens, Hippokratio General Hospital Athens.

Sickle cell disease patients often need regular blood transfusions to improve both the quality of life and survival from the veno-occlusive complications of the disease. Deferasirox, a convenient long acting oral agent, has recently been introduced in clinical practice with promising efficacy. This study aims to evaluate the association of liver stiffness and possible fibrosis with iron deposition and confirm the use of elastography as a validated test of responding to chelation with low cost and easy access. Read More

View Article

Download full-text PDF

Source
https://www.mjhid.org/index.php/mjhid/article/view/2018.049
Publisher Site
http://dx.doi.org/10.4084/MJHID.2018.049DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6131104PMC
September 2018
9 Reads

Economic Burden of Veno-occlusive Disease in Patients With B-cell Acute Lymphoblastic Leukemia in the United States.

Clin Ther 2018 Oct 7;40(10):1711-1719.e1. Epub 2018 Sep 7.

Amgen Inc, South San Francisco, California.

Purpose: The goal of this study was to evaluate the incidence, inpatient mortality, and economic burden of hepatic veno-occlusive disease (VOD) in adults with B-cell acute lymphoblastic leukemia (ALL) in the United States.

Methods: Using MarketScan Commercial Claims and Encounters Database and Medicare Supplemental and Coordination of Benefits Database, data for patients with B-cell ALL from April 1, 2009, to October 31, 2016, were extracted by using diagnosis codes. VOD was identified based on clinical criteria and expert opinions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clinthera.2018.08.005DOI Listing
October 2018
12 Reads

Veno-occlusive disease after high-dose busulfan-melphalan in neuroblastoma.

Bone Marrow Transplant 2018 Sep 4. Epub 2018 Sep 4.

Department of Pediatrics, University of California San Francisco Benioff Children's Hospital, San Francisco, CA, USA.

Survival for high-risk neuroblastoma patients is still suboptimal. Although stem cell transplantation (SCT) is used, there is no consensus as to which conditioning regimen has the greatest efficacy and fewest toxicities. We assessed the incidence of and risk for hepatic veno-occlusive disease (VOD) for neuroblastoma patients who underwent autologous SCT with busulfan and melphalan (BuMel) at eight centers following Children's Oncology Group (COG)-based induction chemotherapy. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41409-018-0298-y
Publisher Site
http://dx.doi.org/10.1038/s41409-018-0298-yDOI Listing
September 2018
11 Reads

Impact of biological agents on the prevalence of chemotherapy associated liver injury (CALI): Multicentric study of patients operated for colorectal liver metastases.

Eur J Surg Oncol 2018 10 27;44(10):1532-1538. Epub 2018 Jul 27.

Department of Pathology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.

Background: The prevalence of chemotherapy associated liver injuries (CALI), especially SOS (sinusoidal obstruction syndrome) and NRH (nodular regenerative hyperplasia) might be reduced since the introduction of routine use of biological agents with chemotherapy in colorectal liver metastases (CRLM).

Methods: One hundred patients with CRLM having undergone at least one liver segment resection were prospectively included, and chemotherapy data recorded. Specimens were reviewed by a single pathologist and CALI were described. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejso.2018.07.050DOI Listing
October 2018
6 Reads

Early Clinical Predictors of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Myeloablative Stem Cell Transplantation.

Biol Blood Marrow Transplant 2019 Jan 3;25(1):137-144. Epub 2018 Aug 3.

Division of Hematologic Malignancies, Department of Medical Oncology, Dana-Farber Cancer Institute, and Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. Electronic address:

Hepatic veno-occlusive disease (VOD), or sinusoidal obstruction syndrome (SOS), is a serious complication of hematopoietic stem cell transplantation (HSCT) with mortality in its severe form exceeding 80%. Although the incidence of VOD/SOS has fallen with contemporary transplantation practices, the increasing use of inotuzumab, the return of gemtuzumab, and the popularity of pharmacokinetic-guided high-dose busulfan may impact incidence. Early intervention with defibrotide improves survival, but prompt diagnosis can be difficult. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2018.07.039DOI Listing
January 2019
5 Reads

New Ultrasound Techniques Challenge the Diagnosis of Sinusoidal Obstruction Syndrome.

Ultrasound Med Biol 2018 11 31;44(11):2171-2182. Epub 2018 Jul 31.

Department of Ultrasound, Zhongshan Hospital, Fudan University, Shanghai, China.

Sinusoidal obstruction syndrome, also known as veno-occlusive disease (SOS/VOD), is a potentially life-threatening complication that can develop after hematopoietic cell transplantation. Clinically, SOS/VOD is characterized by hepatomegaly, right upper quadrant pain, jaundice and ascites, most often occurring within the first 3 wk after hematopoietic cell transplantation. Early therapeutic intervention is pivotal for survival in SOS/VOD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ultrasmedbio.2018.06.002DOI Listing
November 2018
1 Read

[Clinical outcome of allogeneic hematopoietic stem cell transplantation with FLAG sequential busulfan/cyclophosphamide conditioning regimen for refractory/relapsed acute myeloid leukemia].

Zhonghua Nei Ke Za Zhi 2018 Aug;57(8):576-581

Department of Hematology, Peking University First Hospital, Beijing 100034, China.

To investigate the therapeutic effects of allogeneic hematopoietic stem cell transplantation (allo-HSCT) with FLAG sequential busulfan/cyclophosphamide(Bu/Cy) conditioning regimen for refractory/relapsed acute myeloid leukemia. From February 2012 to June 2017, 21 patients with refractory/relapsed acute myeloid leukemia underwent allo-HSCT with FLAG sequential Bu/Cy conditioning regimen. Transplantation-related complications and clinical outcome were retrospectively analyzed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3760/cma.j.issn.0578-1426.2018.08.008DOI Listing
August 2018
1 Read

[Severe Liver Injury Due to Sinusoidal Obstruction Syndrome Induced by Oxaliplatin in a Patient with Resectable Colorectal Liver Metastases].

Gan To Kagaku Ryoho 2018 Jun;45(6):989-992

Dept. of Surgery, Aichi Kouseiren Toyota Kousei Hospital.

A 62-year-old man was diagnosed with liver metastasis of sigmoid colon cancer, which resulted in bowel obstruction. SOX plus bevacizumab therapy was administered to perform hepatectomy, after the artificial anus construction; however, substantial liver dysfunction occurred. Therefore, we only performed primary tumor resection and waited for improvement in liver function. Read More

View Article

Download full-text PDF

Source
June 2018
2 Reads

Direct Intrahepatic Portocaval Shunt for Sinusoidal Obstruction Syndrome Associated with Hepatotoxicity of Pyrrolizidine Alkaloids.

Biomed Res Int 2018 13;2018:9804582. Epub 2018 Jun 13.

Department of Ultrasound, Air Force General Hospital of PLA, Haidian District, Beijing, 100142, China.

We retrospectively identified 89 consecutive patients from January 2004 to January 2012 to investigate efficacy of direct intrahepatic portocaval shunt (DIPS) combined with inferior vena cava (IVC) stenting for sinusoidal obstruction syndrome (SOS) associated with hepatotoxicity of pyrrolizidine alkaloids. Indications for treatment were variceal hemorrhage and/or refractory ascites. Patients were treated with DIPS plus IVC stenting (group A, n=68) or DIPS alone (group B, n=21). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2018/9804582DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6020549PMC
January 2019
3 Reads

Prophylactic recombinant thrombomodulin treatment prevents hepatic sinusoidal obstruction syndrome in high-risk pediatric patients that undergo hematopoietic stem cell transplants.

Pediatr Transplant 2018 11 12;22(7):e13269. Epub 2018 Jul 12.

Department of Pediatrics, Showa University Fujigaoka Hospital, Yokohama, Japan.

Hepatic SOS is a potentially life-threatening complication of conditioning for allogeneic HSCT. rTM is a new drug for treating DIC. We report our experience of the use of rTM as a prophylaxis against SOS in high-risk pediatric patients that underwent HSCT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/petr.13269DOI Listing
November 2018
23 Reads

[A clinical analysis of hepatic veno-occlusive disease after hematopoietic stem cell transplantation].

Zhonghua Nei Ke Za Zhi 2018 Jul;57(7):483-486

Department of Hematology, the First Affiliated Hospital of Guangxi Medical University, Nanning 530021, China.

To analyze the outcome and the prognostic factors of hepatic veno-occlusive disease (HVOD) after hematopoietic stem cell transplantation (HSCT). A total of 797 patients receiving HSCT were analyzed retrospectively. The prophylaxis regimen of HVOD in the First Affiliated Hospital of Guangxi Medical University consisted of low molecular weight heparin and lipoprostaglandin E1 (PGE1). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3760/cma.j.issn.0578-1426.2018.07.003DOI Listing
July 2018
12 Reads

Fulminant hepatitis due to very severe sinusoidal obstruction syndrome (SOS/VOD) after autologous peripheral stem cell transplantation: a case report.

BMC Res Notes 2018 Jul 3;11(1):436. Epub 2018 Jul 3.

Department of Clinical Hematology, Institut de Cancérologie Lucien Neuwirth, 108 Bis Avenue Albert Raimond, 42270, Saint Priest en Jarez, France.

Background: Hepatic veno-occlusive disease, also called sinusoidal obstruction syndrome (SOS/VOD), is a potentially fatal complication of allogeneic or autologous hematopoietic stem cell transplantation. A plethora of transplant and patient-related risk factors predispose to SOS/VOD and should be taken into account for prognosis assessment as well as for adequate therapeutic intervention.

Case Presentation: We describe the case of a mantle cell lymphoma patient who developed a fulminant hepatitis following oxaliplatin-containing intensive chemotherapy and autologous transplantation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13104-018-3533-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6029059PMC
July 2018
6 Reads

The use of defibrotide in blood and marrow transplantation.

Blood Adv 2018 Jun;2(12):1495-1509

Galena Biopharma, San Ramon, CA.

Hepatic veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) is a potentially life-threatening complication of conditioning during hematopoietic stem cell transplantation (HSCT) or chemotherapy without HSCT, with a historically reported mean incidence of 13.7% post-HSCT. Typical symptoms of VOD/SOS may include hyperbilirubinemia, painful hepatomegaly, weight gain, and ascites. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/bloodadvances.2017008375DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6020812PMC
June 2018
12 Reads

Management of hepatic vein occlusive disease after liver transplantation: A case report with literature review.

Medicine (Baltimore) 2018 Jun;97(24):e11076

Department of Organ Transplantation.

Rationale: Hepatic vein occlusive disease (HVOD) is a rare complication after liver transplantation, which is characterized by nonthrombotic, fibrous obliteration of the small centrilobular hepatic veins by connective tissue and centrilobular necrosis in zone 3 of the acini. HVOD after solid organ transplantation has been reported; recently, most of these reports with limited cases have documented that acute cell rejection and immunosuppressive agents are the major causative factors. HVOD is relatively a rare complication of liver transplantation with the incidence of approximately 2%. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000011076DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6024223PMC
June 2018
4 Reads
5.723 Impact Factor

Hepatic veno-occlusive disease following sirolimus-based immune suppression.

Bone Marrow Transplant 2018 Jun 12. Epub 2018 Jun 12.

BMTCI H. Lee Moffitt Cancer Center and Research Institute, Tampa, USA.

Sirolimus-based graft vs. host disease (GVHD) prophylaxis is associated with higher incidence of veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) after allogeneic hematopoietic cell transplantation (HCT). However, whether the clinical manifestations and prognosis of VOD/SOS differs when diagnosed in the setting of sirolimus-based GVHD prophylaxis is not well studied. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-018-0233-2DOI Listing
June 2018
3 Reads

Defibrotide for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome following nontransplant-associated chemotherapy: Final results from a post hoc analysis of data from an expanded-access program.

Pediatr Blood Cancer 2018 Oct 6;65(10):e27269. Epub 2018 Jun 6.

Pediatric Oncology, The Children's Hospital of Philadelphia and the Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.

Background: Hepatic veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) is a potentially fatal complication of conditioning for hematopoietic stem cell transplantation (HSCT) but can occur after nontransplant-associated chemotherapy. Following HSCT, VOD/SOS with multi-organ dysfunction (MOD) may be associated with >80% mortality. Defibrotide is approved to treat severe hepatic VOD/SOS post-HSCT in patients aged >1 month in the European Union and hepatic VOD/SOS with renal or pulmonary dysfunction post-HSCT in the United States. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pbc.27269DOI Listing
October 2018
26 Reads
2.562 Impact Factor

Novel Ultrasonographic Scoring System of Sinusoidal Obstruction Syndrome after Hematopoietic Stem Cell Transplantation.

Biol Blood Marrow Transplant 2018 Sep 24;24(9):1896-1900. Epub 2018 May 24.

Division of Laboratory and Transfusion Medicine, Hokkaido University Hospital, Sapporo, Japan; Department of Hematology, Hokkaido University Hospital, Sapporo, Japan.

Sinusoidal obstruction syndrome (SOS)/hepatic veno-occlusive disease (VOD) is a well-documented complication after hematopoietic stem cell transplantation (HSCT). Transabdominal ultrasonography (US) enables the visualization of blood flow abnormalities and is therefore useful for the diagnosis of SOS/VOD. We herein prospectively evaluated accuracy of a novel US diagnostic scoring system of SOS/VOD based on US findings. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10838791183029
Publisher Site
http://dx.doi.org/10.1016/j.bbmt.2018.05.025DOI Listing
September 2018
6 Reads

Final results from a defibrotide treatment-IND study for patients with hepatic veno-occlusive disease/sinusoidal obstruction syndrome.

Br J Haematol 2018 Jun 16;181(6):816-827. Epub 2018 May 16.

Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

Hepatic veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) is a potentially life-threatening complication of haematopoietic stem cell transplant (HSCT) conditioning and chemotherapy. Defibrotide is approved for treatment of hepatic VOD/SOS with pulmonary or renal dysfunction [i.e. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15267DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6032999PMC
June 2018
4 Reads
4.710 Impact Factor

Haploidentical Donor Transplantation Using a Novel Clofarabine-containing Conditioning Regimen for Very High-risk Hematologic Malignant Neoplasms.

J Pediatr Hematol Oncol 2018 Nov;40(8):e479-e485

Department of Pediatrics, University of Tennessee Health Science Center, Memphis, TN.

Recurrent/refractory hematologic malignancies have a poor prognosis, and there is a need for novel treatment regimens that can be tolerated by this heavily pretreated patient group. Clofarabine has antileukemic activity with an acceptable toxicity profile. In a phase I clinical trial (NCT00824135), we substituted clofarabine for fludarabine in a well-established reduced-intensity conditioning regimen for a T cell-depleted, mismatched-related (haploidentical) donor transplant backbone and explored the maximum tolerated dose of clofarabine in this combination in 15 patients undergoing hematopoietic cell transplantation for recurrent/refractory or secondary leukemia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MPH.0000000000001222DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6197927PMC
November 2018
5 Reads
0.960 Impact Factor

Sinusoidal Obstruction Syndrome (Veno-occlusive Disease) Following Hematopoietic Stem Cell Transplant: Insights and Therapeutic Advances.

Anticancer Res 2018 05;38(5):2597-2605

The George Washington University School of Medicine, Washington, DC, U.S.A.

Hepatic sinusoidal obstruction syndrome (SOS) is a rare fatal clinical entity seen following hematopoietic stem cell transplant (HSCT). It is more commonly reported to occur following allogeneic HSCT compared to autologous HSCT. Historically, it is known as hepatitis following HSCT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.12501DOI Listing
May 2018
1 Read

Hepatic veno-occlusive disease related to Gynura segetum: A case report.

Medicine (Baltimore) 2018 Apr;97(17):e0552

Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital, the Affiliated Cancer Hospital of Xiangya School of Medicine.

Introduction: Hepatic veno-occlusive disease (HVOD), as known as hepatic sinusoidal obstruction syndrome (HSOS), is an obliterative venulitis of the terminal hepatic venules, which is responsible for considerable mortality. The potential mechanism is destruction of hepatic sinusoidal endothelial cells (SEC), with sloughing and downstream occlusion of terminal hepatic venules. Here, we report a case of HVOD who have a history of ingestion of Gynura segetum for 1 month. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000010552DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5944499PMC
April 2018
4 Reads

[Sinusoidal obstruction syndrome after BeAM conditioning regiment for autologous stem cell transplantation: Imputability of bendamustine? Report of two cases and literature review].

Rev Med Interne 2018 Nov 16;39(11):882-885. Epub 2018 Apr 16.

Service d'immunologie clinique et de médecine interne, centre national de référence des maladies auto-immunes rares, hôpitaux universitaires de Strasbourg, 67091 Strasbourg, France. Electronic address:

Introduction: Sinusoidal obstruction syndrome is a rare complication of autologous hematopoietic stem cell transplantation. This syndrome is mainly described following conditioning regiment with busulfan, cyclophosphamide and/or total body irradiation.

Case Reports: We report for the first time two cases of sinusoidal obstruction syndrome occurring lately after BeAM conditioning regiment (bendamustine, etoposide, aracytine, melphalan) for autologous stem cell transplantation in patients treated for malignant lymphoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.revmed.2018.03.009DOI Listing
November 2018

FDA Approval Summary: Mylotarg for Treatment of Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia.

Oncologist 2018 Sep 12;23(9):1103-1108. Epub 2018 Apr 12.

Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.

On September 2, 2017, the U.S. Food and Drug Administration approved gemtuzumab ozogamicin (GO; Mylotarg; Pfizer, New York City, NY) for treatment of relapsed or refractory (R/R) CD33-positive acute myeloid leukemia (AML) in patients 2 years of age and older. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2017-0604DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6192608PMC
September 2018
14 Reads

[Treatment of four cases of Fanconi anemia by allogeneic hematopoietic stem cell transplantation with low intensity conditional regimen].

Zhonghua Xue Ye Xue Za Zhi 2018 Mar;39(3):231-235

Department of Hematology and Oncology, Children's Hospital of Soochow University, Suzhou 215003, China.

To evaluate the efficiency and safety of low intensity conditional regimen for children with Fanconi anemia (FA) receiving allogenic hematopoietic stem cells transplantation (allo-HSCT). Four patients diagnosed as Fanconi anemia were enrolled in this study. One patient received HLA-identical sibling donor hematopoietic stem cell transplantation, two patients underwent unrelated donor matched (UD) HSCT, and one patient received unrelated cord blood transplantation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2018.03.011DOI Listing

Risk assessment of pyrrolizidine alkaloids in food of plant and animal origin.

Food Chem Toxicol 2018 May 7;115:63-72. Epub 2018 Mar 7.

Federal Institute for Risk Assessment (BfR), Max-Dohrn-Strasse 10, 10589 Berlin, Germany. Electronic address:

Acute liver toxicity, specifically in the form of hepatic veno-occlusive disease (HVOD), is known from reports on human poisonings following ingestions of 1,2-unsaturated pyrrolizidine alkaloids (PAs) containing herbs. Recently PA exposure via common foods contaminated via PA-producing plants raised concern, especially regarding the potential of genotoxicity and carcinogenicity. The health risks related to the estimated exposures to PAs from food were assessed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.fct.2018.03.005DOI Listing
May 2018
7 Reads

Modified triangular hepatic vein reconstruction for preventing hepatic venous outflow obstruction in pediatric living donor liver transplantation using left lateral segment grafts.

Pediatr Transplant 2018 05 1;22(3):e13167. Epub 2018 Apr 1.

Transplantation Center, National Center for Child Health and Development, Tokyo, Japan.

HVOO can be a critical complication in pediatric LDLT. The aim of this study was to evaluate a modified triangular technique of hepatic vein reconstruction for preventing HVOO in pediatric LDLT. A total of 298 pediatric LDLTs were performed using a left lateral segment graft by 2 methods for reconstruction of the hepatic vein. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/petr.13167DOI Listing
May 2018
7 Reads

Defibrotide for Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease Prophylaxis in High-Risk Adult Patients: A Single-Center Experience Study.

Biol Blood Marrow Transplant 2018 Jul 1;24(7):1471-1475. Epub 2018 Mar 1.

Hematology and Cellular Therapy Service, Saint Antoine Hospital, AP-HP, Paris, France; Université Pierre et Marie Curie (UPMC), Sorbonne Universités, Paris, France; INSERM, UMRs 938, Paris, France. Electronic address:

Sinusoidal obstruction syndrome (SOS), also known as hepatic veno-occlusive disease (VOD), is a serious complication after hematopoietic stem cell transplantation (HSCT). SOS/VOD usually occurs within 3 weeks of HSCT, but the 2016 European Society for Blood and Marrow Transplantation diagnosis criteria have been revised to include late forms. Prophylactic use of defibrotide is recommended in the pediatric setting, but its value remains uncertain in the adult population. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2018.02.015DOI Listing
July 2018
21 Reads

The involvement of Nrf2 antioxidant signalling pathway in the protection of monocrotaline-induced hepatic sinusoidal obstruction syndrome in rats by (+)-catechin hydrate.

Free Radic Res 2018 Apr;52(4):402-414

a MOE Key Laboratory for Standardization of Chinese Medicines and Shanghai Key Laboratory of Compound Chinese Medicines , Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine , Shanghai , China.

Hepatic sinusoidal obstruction syndrome (HSOS) is a rare and life-threatening liver disease. (+)-Catechin is a natural dietary flavonol with high antioxidant capacity. This study aims to investigate the involvement of nuclear factor erythroid 2-related factor 2 (Nrf2) antioxidant signalling pathway in the protection of (+)-catechin hydrate (CAT) against monocrotaline (MCT)-induced HSOS. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10715762.2018.1437914DOI Listing
April 2018
7 Reads

Re: Diagnostic performance of contrast-enhanced CT-scan in sinusoidal obstruction syndrome induced by chemotherapy of colorectal liver metastases: Radio-pathological correlation.

Authors:
Sophie Cayet

Eur J Radiol 2018 03 2;100:155. Epub 2018 Feb 2.

Trousseau Hospital, Radiology, Avenue de la République, 37170, Chambray-lès-Tours, Tours, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejrad.2018.01.019DOI Listing
March 2018
3 Reads

Re: Diagnostic performance of contrast-enhanced CT-scan in sinusoidal obstruction syndrome induced by chemotherapy of colorectal liver metastases: Radio-pathological correlation.

Eur J Radiol 2018 03 31;100:154. Epub 2018 Jan 31.

Department of Radiology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine & Guangdong Provincial Hospital of Chinese Medicine, 111 Da De Lu, Guangzhou, Guangdong Province 510120, PR China. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejrad.2017.12.016DOI Listing
March 2018
1 Read

The role of continuous renal replacement therapy in the management of acute kidney injury associated with sinusoidal obstruction syndrome following hematopoietic cell transplantation.

Pediatr Transplant 2018 03 1;22(2). Epub 2018 Feb 1.

Pediatric Blood and Marrow Transplant Program, Nationwide Children's Hospital, Ohio State University College of Medicine, Columbus, OH, USA.

Maintaining fluid balance, pre- and post-MA-HCT is essential and usually requires frequent administration of diuretics. Hepatic sinusoidal obstructive syndrome is potentially life-threatening, especially when associated with AKI and MOF. This study describes six patients who developed AKI-associated SOS and diuretic-resistant FO who subsequently underwent CRRT using standardized management guidelines for fluid balance post-HCT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/petr.13139DOI Listing
March 2018
14 Reads

Identification and Management: Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease Eelated to Hematopoietic Stem Cell Transplantation
.

Clin J Oncol Nurs 2018 02;22(1):E7-E17

Westchester Medical Center.

Background: Sinusoidal obstruction syndrome (SOS), also called hepatic veno-occlusive disease (VOD), is a potentially life-threatening complication of hematopoietic stem cell transplantation (HSCT) that affects about 1 in 7 patients undergoing this procedure. SOS/VOD is caused by the conditioning regimens administered prior to HSCT; in some cases, SOS/VOD results from chemotherapy alone. SOS/VOD usually develops within three weeks following HSCT; however, it can have later onset. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1188/18.CJON.E7-E17DOI Listing
February 2018
3 Reads

Late-Onset Hepatic Veno-Occlusive Disease after Allografting: Report of Two Cases with Atypical Clinical Features Successfully Treated with Defibrotide.

Mediterr J Hematol Infect Dis 2018 1;10(1):e2018001. Epub 2018 Jan 1.

A.O.U. Città della Salute e della Scienza di Torino, Dipartimento di Oncologia, SSD Trapianto allogenico di cellule staminali, Torino, Italy.

Hepatic Veno-Occlusive Disease (VOD) is a potentially severe complication of hematopoietic stem cell transplantation (HSCT). Here we report two patients receiving an allogeneic HSCT who developed late onset VOD with atypical clinical features. The two patients presented with only few risk factors, namely, advanced acute leukemia, a myeloablative busulphan-containing regimen and received grafts from an unrelated donor. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4084/MJHID.2018.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5760078PMC
January 2018
17 Reads

Defibrotide sodium for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome.

Expert Rev Clin Pharmacol 2018 Feb 5;11(2):113-124. Epub 2018 Jan 5.

f Hematology Department , Hôpital Saint Antoine, AP-HP, Université Pierre & Marie Curie , Paris , France.

Introduction: Hepatic veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) is an unpredictable condition associated with endothelial-cell damage due to conditioning for hematopoietic stem-cell transplantation (HSCT) or chemotherapy without HSCT. Mortality in patients with VOD/SOS and multi-organ dysfunction (MOD) may be >80%. Areas covered: Defibrotide is the only approved drug for the treatment of severe hepatic VOD/SOS after HSCT in the European Union and hepatic VOD/SOS with renal or pulmonary dysfunction in the United States. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17512433.2018.1421943DOI Listing
February 2018
19 Reads

Evaluation of the therapeutic effects of rice husk nanosilica combined with platelet-derived growth factor in hepatic veno-occlusive disease.

Biochem Cell Biol 2018 10 4;96(5):682-694. Epub 2018 Jan 4.

b Chemistry Department, Faculty of Science, Ain Shams University, Abbassia, Cairo, Egypt.

Veno-occlusive disease is an important pattern of hepatotoxicity associated with antineoplastic drugs. The study investigated the possible therapeutic effects of RHS nanoparticles combined with a PDGF on veno-occlusive disease (VOD) in liver elicited in rats with DAC. In this work, nanosilica (SiO) was successfully prepared from rice husk, and its physicochemical characteristics were investigated using EDX, XRD, N adsorption-desorption isotherm, SEM, and TEM. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1139/bcb-2017-0248DOI Listing
October 2018
6 Reads

Gallbladder wall oedema and ascites are independent predictors of progression to hepatic veno-occlusive disease for children with hematopoietic stem cell transplantation.

Eur Radiol 2018 Jun 2;28(6):2291-2298. Epub 2018 Jan 2.

Department of Pediatrics, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.

Objectives: To evaluate the predictive value of ultrasonography in children with clinically suspicious hepatic veno-occlusive disease (VOD) after hematopoietic stem cell transplantation (HSCT).

Methods: Among 216 children who underwent HSCT, 70 also underwent colour Doppler ultrasonography. Of these, 59 had only one sign/symptom, which did not fulfil the diagnostic criteria (clinical suspicion of VOD) at that time. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00330-017-5137-9DOI Listing
June 2018
12 Reads

Hepatobiliary and Pancreatic: Pregnancy induced hepatic veno-occlusive disease requiring liver transplantation.

J Gastroenterol Hepatol 2018 Jan;33(1)

Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jgh.13975DOI Listing
January 2018
5 Reads

Hepatic veno-occlusive disease during isavuconazole administration.

J Chemother 2018 02 26;30(1):63-64. Epub 2017 Dec 26.

d Infectious Diseases Unit , Istituto Giannina Gaslini , Genoa , Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1120009X.2017.1418619DOI Listing
February 2018
6 Reads

Changes of liver hemodynamic and elastography parameters in patients with colorectal liver metastases receiving preoperative chemotherapy: "a note of caution".

World J Surg Oncol 2017 Dec 16;15(1):224. Epub 2017 Dec 16.

Liver Surgery and Transplant Unit, Department of Surgery, Institut de Malalties Digestives i Metabòliques Hospital Clinic Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain.

Background: New systemic chemotherapy agents have improved prognosis in patients with colorectal liver metastases (CLM), but some of them damage the liver parenchyma and ultimately increase postoperative morbidity and mortality after liver resection. The aims of our study were to determine the degree of hemodynamic and pathological liver injury in CLM patients receiving preoperative chemotherapy and to identify an association between these injuries and postoperative complications after liver resection.

Methods: This is a prospective descriptive study of patients with CLM receiving preoperative chemotherapy before curative liver resection from November 2013 to June 2014. Read More

View Article

Download full-text PDF

Source
https://wjso.biomedcentral.com/articles/10.1186/s12957-017-1
Publisher Site
http://dx.doi.org/10.1186/s12957-017-1290-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5732417PMC
December 2017
7 Reads

Noninvasive assessment of hepatic sinusoidal obstructive syndrome using acoustic radiation force impulse elastography imaging: A proof-of-concept study in rat models.

Eur Radiol 2018 May 7;28(5):2096-2106. Epub 2017 Dec 7.

Department of Radiology and Research Institute of Radiology, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Korea.

Objectives: To determine the feasibility of acoustic radiation force impulse (ARFI) elastography in the evaluation of hepatic sinusoidal obstruction syndrome (SOS) in rat models.

Methods: Rat SOS models of various severities were created by monocrotaline gavage (n = 40) or by intraperitoneal injection of 5-fluorouracil, leucovorin and oxaliplatin (FOLFOX) (n = 16). Liver shear-wave velocity (SWV) was measured using ARFI elastography. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00330-017-5179-zDOI Listing
May 2018
7 Reads

CT Features of Hepatic Veno-occlusive Disease: A Meta-analysis.

Acad Radiol 2018 Mar 27;25(3):328-337. Epub 2017 Nov 27.

Department of Respiratory Medicine, The Second XiangYa Hospital, Central South University, Changsha, Hunan 410011, China.

Rationale And Objective: The computed tomography (CT) features of hepatic veno-occlusive disease (HVOD) could play a role in its diagnosis. We aimed to perform a meta-analysis of studies examining the CT features of HVOD.

Methods: Relevant studies published up to May 3, 2017 were searched in major electronic databases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.acra.2017.10.012DOI Listing
March 2018
5 Reads
2.080 Impact Factor